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Abstract
Traumatic brain injury (TBI) represents a leading contributor to long-term neu-
rological damage. Though TBI is a leading cause of death and neurological damage 
worldwide, there exists no therapeutic treatments to alleviate deleterious secondary 
injury due to neuroinflammation. The continuum of pro- and anti-inflammatory 
response elicited by TBI is suggested to play a key role in the outcome of TBI; 
however, the underlying mechanisms remain poorly defined. This chapter explores 
rodent models of injury used to study the disease pathology of TBI, as well as the 
major contributions of the peripheral immune response following injury. Further, 
this chapter discusses the influence of individual immune cell types on neuroinflam-
mation following TBI, focusing on peripheral monocyte/macrophages, their polar-
ization state, and the current literature surrounding their behavior within the TBI 
milieu. Finally, cell-to-cell contact regulators that effect peripheral-induced neuroin-
flammation and may serve as novel targets for therapeutics will be highlighted.
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1. Introduction
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in the 
United States and worldwide [1–4]. TBI results from an injury to the brain following 
exposure to external physical forces including falls, car accidents, explosive blasts, 
and assault [5, 6]. These injuries often have long-term consequences to the health 
of injured individuals, and few effective treatments are currently available [6]. The 
pathophysiology is characterized by damage to the neuronal and glial cells of the 
brain as well as the associated vasculature [6], and the role of inflammation as a 
causative agent of tissue injury has emerged as a focus of TBI research [7]. Preclinical 
research focusing on the mechanisms underlying secondary inflammation and 
treatment of TBI employs various animal models [8]. This review will discuss TBI as 
a public health problem, the pathology of TBI and the significance of the peripheral 
immune response in the outcome of TBI in human and animal models.
2. Prevalence of TBI
Traumatic brain injury is a major cause of death and disability in the United 
States and worldwide [1–4]. An estimated 69 million people sustain a TBI each year 
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around the world [9]. In the United States, incidence of TBI has risen steadily over 
recent years. An average of 1.7 million TBIs occurred per year from 2002 to 2006 
[1], but an estimated 2.8 million TBIs occurred in 2013 [4]. There is a gender dispar-
ity in groups most affected by TBI—in the United States, males are more commonly 
affected than females. Age group differences are also evident in TBI prevalence, 
with young children, young adults, and the elderly most frequently suffering from 
TBI. The specific age groups that most commonly sustain TBIs are ages 0–4 years, 
15–24 years, and 75 years and older [4]. Traumatic brain injuries arise from a variety 
of causes including traffic accidents, falls, abuse, sports injuries, and traumatic 
impact with an object [4, 5]. The most prevalent causes of injury vary predictably 
with patient age. Injuries in younger patients are most commonly associated with 
sports activities or high-risk behaviors such as distracted driving, while injury in 
the older population of patients is more frequently associated with falls [5]. These 
events cause injuries of a range of clinical severities including mild, moderate, and 
severe TBI. In the clinical setting, these injuries are most frequently classified using 
the Glasgow Coma Score (GCS) [10]. The GCS assesses overall consciousness of 
the patient and classifies injury severity based on eye, motor, and verbal responses 
to stimuli [5, 10]. Scores range from 3 to 15. Higher scores correlate with decreased 
injury severity—for clinical classification purposes, a GCS range of 13–15 has been 
used to demarcate mild injury, 9–12 for moderate injury, and 8 or less to indicate 
severe TBI [5]. Imaging modalities including CT and MRI are also used to further 
assess the severity of TBI and inform prognosis [10].
3. Pathology of TBI
A traumatic brain injury may be defined as an injury to brain tissue caused by 
direct external force [10]. The physical impact of TBI initiates a plethora of down-
stream processes with deleterious effects on neuronal and glial tissue. Overall, the 
pathophysiology of a TBI can be divided into primary and secondary phases of 
injury [5, 10–12]. The primary phase of injury includes the cellular damage caused at 
the instant of injury by the direct mechanical impact of trauma. Primary injury can 
manifest as cell death, hemorrhage, and/or diffuse axonal injury. First, neurons and 
supporting vasculature can be directly torn by the shear forces of injury. This dam-
age to the neurovascular network results in intracranial hemorrhage, which can lead 
to increased intracranial pressure as blood builds up inside the skull. Intracranial 
bleeding can also generate hematomas. Both increased intracranial pressure and 
hematoma formation have negative impacts on neural recovery [11, 13]. Primary 
injury can also encompass diffuse axonal injury. Diffuse axonal injury is damage to 
neurons going beyond the initial lesion area, caused by dynamic forces spreading 
through the brain from the primary impact [11]. These physical forces resulting from 
traumatic brain injury can be either linear accelerational forces or rotational forces. 
Since neural tissue is elastic and does not have a strong internal structure, the brain 
has little tolerance for this disruption and is very susceptible to injury from these 
forces [12]. Primary injury also disturbs autoregulation of cerebral blood flow and 
cellular metabolism. Normal control mechanisms for blood flow and metabolism fail 
due to the cellular damage of TBI, resulting in cellular effects similar to those seen 
in ischemic stroke. As the massive damage overwhelms cellular metabolism, ATP 
production cannot match demand, and neuronal and glial supplies of ATP become 
inadequate to fuel cellular ion pumps. The resulting dysregulation of ion flow 
initiates various downstream pathways leading to necrosis, apoptosis, and oxidative 
damage [14]. Additional mechanisms of secondary injury have been described and 
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include the long-term changes resulting from the physiological processes triggered 
by the primary phase of injury [12].
3.1 Neuroinflammation
Neuroinflammation plays a major role in the secondary phase of injury. While 
all resident brain cells are involved in some way in the response to TBI, the role of 
microglia, the resident immune cells of the brain, in neuroinflammation has been 
particularly well-studied. When brain injury occurs, cells damaged in the primary 
phase of injury release cell signals known as damage-associated molecular patterns 
(DAMPs). In the early stages of injury, resident microglial cells are activated by 
these DAMPs and migrate to the injury site [7, 15]. These cells have a profound effect 
on both acute and chronic injury processes as they secrete both pro- and anti-
inflammatory cytokines and can remain activated for up to 18 years after TBI [7, 16]. 
Cytokines released by microglia have a plethora of effects including alteration of 
local blood flow and modification of the blood-brain barrier (BBB) [15]. Microglia 
also assist in walling off the injured area in a protective effort to prevent the spread 
of bleeding and cellular damage. However, these cells can also generate additional 
reactive oxygen species (ROS) with damaging effects on cells [17]. While glial cell 
activation is a key part of the secondary phase of TBI, there is also an important role 
for the peripheral immune system in TBI recovery. The central nervous system is 
typically viewed as an immune-privileged site, with few or no peripheral-derived 
immune cells present. However, following TBI, the blood-brain barrier is damaged, 
allowing infiltration of peripheral-derived circulating immune cells including 
neutrophils, macrophages, and lymphocytes [17]. Glutamate excitotoxicity, oxida-
tive stress, and neuroinflammation all contribute to the cellular damage observed 
in the secondary phase of injury, and the long-term damage resulting from these 
processes can be extensive. This secondary phase of injury is the primary target for 
TBI therapeutics—while efforts can be made to reduce TBI incidence, once a TBI has 
occurred nothing can be done to treat primary injury. Therefore, potential TBI treat-
ments are aimed at reducing damage from the secondary phase of injury [14].
4. Rodent models of TBI
Multiple rodent models have been used to study the role of inflammation in TBI. 
Due to the variety of injury causes and individual patient health effects, human 
TBI exhibits multifaceted disease processes, and different animal models are used 
to recapitulate different aspects of human injury. Here, we discuss three common 
mouse models of TBI: weight drop, fluid percussion injury (FPI), and controlled 
cortical impact (CCI). All three of these models generate TBI by direct impact, 
either applied directly to the brain through a craniectomy or applied to the intact 
skull. While each of these models replicate certain features of human TBI, no one 
model fully expresses the varied picture of clinical TBI.
• Weight drop and fluid percussion injury are both used to produce diffuse 
injury in rodent models of TBI. Weight drop injury relies on gravity-driven fall 
of the weight to generate injury. Injury severity can be controlled by adjusting 
both the height of the drop and the mass of the weight used. Modification of 
injury severity allows this model to reproduce features of mild, moderate, or 
severe TBI. Weight drop injury results in cortical cell death, cerebral edema, 
neuroinflammation, and blood-brain barrier compromise, and this method of 
Advancement and New Understanding in Brain Injury
4
injury is relatively time-efficient to perform [18, 19]. In addition, weight drop 
injury results in demonstrable cognitive deficits, which may reproduce features 
of human TBI [20].
• FPI can also reproduce certain histological features of human TBI and can be 
modified to generate different severities of injury. The FPI method is one of 
the most commonly used models of experimental TBI and can be adjusted to 
generate mild, moderate, or severe TBI [21]. Fluid percussion injury is per-
formed using the injection of fluid into the cranial cavity, generating injury 
as a pressure wave spreads through the fluid applied to the brain [8, 22]. This 
model results in cortical contusion, hemorrhage, inflammation, diffuse axonal 
injury, and gliosis, with accompanying memory and motor deficits [21, 23, 24]. 
Application of FPI causes both focal and diffuse damage to the brain and has 
been used to assess multiple prospective TBI therapeutics [25].
• CCI generates injury by application of a mechanical focal impact to the brain 
using a controlled piston. This technique was initially developed to replicate 
features of injuries caused by automobile accidents but is now commonly 
used to study multiple aspects of focal TBI pathology [26]. Controlled cortical 
impact machines allow modification of the depth, velocity, dwell time, and 
angle of the impact, as well as variation of the size and shape of the impactor 
tip. These highly reproducible features make the CCI model especially well-
suited to induce a wide range of injury severities, and the tight control of injury 
parameters is an important advantage of this model [26, 27]. The CCI method 
of experimental TBI typically includes a craniotomy before impact to the intact 
dura mater, although this method can also be used to produce closed-head 
injury [27]. Injury induced by CCI replicates many histopathological changes 
seen in human TBI, including cortical contusion, blood-brain barrier compro-
mise, inflammation, and oxidative stress [26]. Corresponding to the histologi-
cal features observed in this model, CCI results in functional deficits, including 
memory, learning, and motor deficits similar to those observed in human TBI 
patients [26]. These deficits are observed in both the acute and chronic periods, 
while other models including FPI less frequently report the chronic persistence 
of cognitive deficits [27]. The CCI model also has an overall higher survival rate 
compared to the fluid percussion model [26]. The reproducibility, tight control 
of experimental parameters, persistence of cognitive deficits, and high survival 
rate induced by CCI make it an excellent model for TBI research. For these rea-
sons, the work outlined in this dissertation takes advantage of the CCI model.
5. Peripheral-derived immune cell response to TBI
The peripheral-derived immune cell response is a key feature of the physiologic 
response to traumatic brain injury, which can have both positive and negative 
effects. The central nervous system is typically regarded as an immune-privileged 
site due to the action of the blood-brain barrier (BBB), which prevents peripheral 
immune cells from readily entering CNS tissue [7, 15]. However, following TBI, the 
integrity of the blood-brain barrier is compromised by a variety of mechanisms, 
allowing infiltration of peripheral-derived immune cells into brain parenchyma 
[28]. Various immune cells including neutrophils, macrophages, and lymphocytes 
have been shown to infiltrate the lesion area following injury, releasing cytokines 
that influence recovery [17]. These peripheral immune cells have a profound effect 
on injury recovery—impact of these infiltrating cells can be either beneficial or 
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deleterious to recovery depending on the specific cells and mechanisms involved. 
While all of these cell types may affect TBI recovery, macrophages in particu-
lar have been a focus of TBI research [29]. This review will discuss the general 
mechanisms of blood-brain barrier compromise after TBI and survey the effects of 
peripheral immune cell infiltration, with a focus on macrophages.
5.1 Blood-brain barrier compromise and immune cell infiltration in TBI
The blood-brain barrier (BBB) forms a protective layer separating the CNS from 
the surrounding environment, including circulating peripheral immune cells. The 
brain is typically regarded as an immune-privileged site due to the operation of the 
BBB—under normal physiologic conditions, peripheral immune cells in the vascu-
lature cannot enter CNS tissue [7, 15]. The healthy brain exists in a tightly regulated 
system, and proper operation of the BBB is critical in maintenance of the correct 
microenvironment for healthy neural function [30]. Multiple cell types including 
brain endothelial cells, astrocytes, and pericytes compose the BBB [30]. Traumatic 
brain injury compromises the BBB by direct damage to the cells composing this 
barrier. The direct damage to cerebral vasculature and disruption of endothelial 
tight junctions allows entry of immune cells and proteins from the vasculature into 
cerebral tissue [28, 31]. Rising calcium concentrations activate caspases in endothe-
lial cells, initiating apoptosis of brain endothelial cells and resulting in additional 
damage to the BBB [28]. The glutamate excitotoxicity observed in TBI also has been 
shown to increase production of reactive oxygen and nitrogen species (known as 
oxidative stress), causing further apoptosis of brain endothelial cells [31]. Reactive 
oxygen species can also increase migration of peripheral monocytes through up-
regulation of cellular adhesion molecules [31]. The physical damage to brain endo-
thelial and glial cells combined with the activation of apoptotic and stress-related 
pathways in the endothelium that disrupt tight junctions can increase BBB perme-
ability, allowing circulating peripheral immune cells to enter the brain. Massive 
influx of peripheral immune cells, induced by brain-derived cytokine release (IL-6, 
TNF, IL-1β, etc.) at the lesion area over time, further contributes to BBB damage. 
Additional cytokine, matrix metallopeptidase (MMP), and reactive oxygen spe-
cies (ROS) released by activated neutrophils and monocyte/macrophages further 
disrupt the BBB via down-regulation of tight junction proteins as well as through 
recruitment of additional inflammatory cells [28, 31–34]. An overview of the major 
peripheral immune cell response is depicted in Figure 1.
5.2 Immune cell-specific contribution to TBI
Neutrophils: Neutrophils arrive at the lesion area in the early stages of injury—
these cells migrate to the area of injury and infiltrate damaged brain tissue within the 
first 24 hours postinjury [33]. These cells are recruited by the release of IL-8, a che-
moattractant cytokine known to be generated in the early stage of TBI [35]. Numbers 
of circulating neutrophils rise significantly in the acute phase of TBI. One study 
found that neutrophils present following TBI appear to be less susceptible to apop-
tosis than neutrophils in uninjured patients, which may contribute to the increased 
numbers observed [36]. In contrast to the few studies implicating a positive role for 
neutrophils in TBI recovery [33, 37], numerous show deleterious effects. One study, 
using the CCI model, found that neutrophil depletion improved tissue recovery. 
Neutrophil-depleted mice in this study showed decreased cell death and tissue loss 
following TBI [38]. Another study assessed the effects of decreased immune cell 
infiltration following TBI via administration of anti-intercellular adhesion molecule 
1 (ICAM1) antibody in a fluid percussion model of rat TBI. Rats given anti-ICAM1 
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showed decreased neutrophil infiltration following injury 26 hours following TBI, 
which correlated with increased motor recovery [39]. Several mechanisms have 
been suggested to explain these negative effects. Some studies have indicated that 
neutrophils bind endothelial cells and platelets after TBI, decreasing blood flow and 
promoting ischemia [33]. As previously mentioned, neutrophils can also damage 
the BBB through release of MMPs and reactive oxygen and nitrogen species [33]. In 
addition, many of the cytokines generated by neutrophils following TBI have been 
Figure 1. 
Overview of major peripheral immune cell response to TBI.
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shown to have negative effects on neural recovery. These cytokines include IL-9, 
IL-12, CXCL5, and TNFα. IL-9 can increase the damage caused by excitotoxicity 
following TBI, and high levels of IL-12 have been correlated with poor postinjury 
outcome (Figure 1). CXCL5 contributes to BBB compromise, and TNFα plays a role 
in neurotoxicity [33]. However, other studies have found that infiltration of periph-
eral cells in the acute stage of injury has little effect on recovery, suggesting instead 
that infiltration of peripheral-derived monocytes in the later stages of injury (greater 
than 48 hours after injury) has the greatest influence on injury progression [7].
Monocytes: The role of monocyte/macrophages has been particularly well-studied 
in regard to the effects of infiltrating peripheral-derived immune cells after TBI. 
Although a minority in terms of numbers of circulating immune cells, composing 
only 5–10% of the peripheral immune cell population, monocytes play an important 
role in TBI recovery [36]. Monocytes are the primary infiltrating immune cells 
observed at 3–5 days following injury [29]. While some studies have even argued that 
peripheral monocytes are the most prominent infiltrating immune cell at 24 hours 
postinjury as well [40]. Circulating monocytes can display pro- or anti-inflamma-
tory properties. When monocytes migrate into affected tissue, they mature into 
macrophages with pro- or anti-inflammatory characteristics [36]. These cells can 
have a neuroprotective effect via phagocytosis of dead cell debris, release of growth 
factors, and production of anti-inflammatory cytokines. Monocyte/macrophages 
also release granulocyte-macrophage colony-stimulating factor (GM-CSF), which 
may have a neuroprotective effect through promotion of stem cell differentiation 
and suppression of apoptotic pathways [41]. However, monocyte/macrophages may 
have differing effects on TBI recovery depending on their inflammatory profile.
While monocyte/macrophages may be beneficial in some aspects of TBI recov-
ery, other studies have found that these cells may also negatively affect neural recov-
ery through different mechanisms. One study assessed the influence of macrophages 
on TBI recovery using a chemokine CC ligand-2 (CCL2) knockout mouse model. 
This study found increased levels of CCL2 following TBI in both human patients 
and in a murine weight drop injury model. CCL2 knockout mice showed decreased 
macrophage accumulation and smaller lesion volumes at 2 and 4 weeks after injury 
[42]. One study showed that depletion of monocytes using clodronate liposomes 
decreased neutrophil infiltration and edema and resulted in improved neurobehav-
ioral recovery [43]. Several mechanisms have been suggested by which macrophages 
could exert neurotoxic effects. Infiltrating macrophages may release reactive oxygen 
and nitrogen species, increase additional recruitment of neutrophils and monocytes, 
and generate multiple pro-inflammatory cytokines including TNF, IL-1β, and IL-6 
(Figure 1) [41]. The apparent discrepancy between the neurodegenerative and 
pro-resolving effects of macrophages following TBI is most likely due to the release 
of both pro- and anti-inflammatory signals from these cells, with corresponding 
positive or negative effects [29]. As previously mentioned, monocytes are capable 
of maturing into macrophages with either pro- or anti-inflammatory characteristics 
[36]. These two populations are traditionally defined as M1 (pro-inflammatory) and 
M2 (anti-inflammatory) macrophages. Although the overall balance between these 
phenotypes is driven by injury processes [44], their differential characteristics and 
the mechanisms underlying their fate choice remain under investigation.
6. The M1/M2 continuum in TBI
Monocyte/macrophages display different phenotypes depending on the cellular 
microenvironment. Classical macrophages, called M1 macrophages, specialize 
in promoting inflammation and phagocytosing pathogens. The second class of 
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macrophages, called M2 macrophages, serves to promote tissue recovery [45]. 
Macrophages are a critical part of the tissue repair process following injury, but 
these cells can be either helpful or damaging depending on M1/2 status. Following 
TBI, macrophage polarization toward the M1 phenotype has been associated with 
neurodegeneration, while polarization toward the M2 phenotype has been shown to 
reduce oxidative stress [46]. However, these classes are not absolute—macrophages 
respond to their cellular environment to become more or less M1/2, existing on 
a continuum with M1 and M2 subcharacteristics at either end [45]. The varied 
expression of M1 pro-inflammatory vs. M2 pro-recovery traits can be a critical fac-
tor in recovery during the peripheral-derived inflammatory response to TBI.
6.1  Classical role of macrophages as pro-inflammatory cells in TBI  
(M1 phenotype): time course
The classically activated or M1 phenotype macrophages are known to function 
as pro-inflammatory cells. Early studies indicated that these cells become activated 
by a combination of IFNγ signaling and either direct TNF signaling or Toll-like 
receptor-induced production of TNF, usually triggered by lipopolysaccharide 
(LPS) [47]. In the typical response to wound healing outside the CNS, these cells 
are important in protection against bacterial infection. M1-polarized macrophages 
generate reactive oxygen species and also activate inducible nitric oxide synthase 
(iNOS) to generate nitric oxide as well as an array of pro-inflammatory cytokines 
including IL-12, TNFα, IL-6, IL-1β, and nitric oxide [47, 48]. Identification of M1 
macrophages is typically done by measuring gene expression of characteristic mark-
ers including IL-12, IL-1β, iNOS, TNFα, and IL-6 [46]. High levels of CCR2 with 
low CX3CR1 expression have also been used as an indicator of pro-inflammatory 
status in macrophages [49]. Bystander tissue damage from M1 macrophages can be 
catastrophic in the normally immune-privileged setting of the CNS.
Peripheral-derived macrophages have been shown to rapidly infiltrate the 
injured brain within the first 1–3 days postinjury [46]. Although both M1 and M2 
macrophages are likely present at this stage, early studies of macrophage polariza-
tion following TBI indicated that the M1 phenotype predominates in the initial 
response to brain trauma [48]. CCI-induced increase in expression of pro-inflamma-
tory markers has been demonstrated as early as 6 hours following injury, suggesting 
that macrophages expressing M1 traits are a key part of the acute response to TBI 
[46]. One study found that increases in the number of IL-12-expressing macro-
phages/microglia were evident by 24 hours following CCI injury, and the number 
remained increased compared to sham controls out to 7 days postinjury [46]. Other 
work demonstrated that either macrophages polarized toward the M1 phenotype or 
a transitional phenotype between M1/2 (to be discussed later) become predominant 
over M2 phenotype by 7 days following CCI injury. This phenomenon correlates 
with neurodegeneration [46].
Based on these reports, macrophages seem to be skewed toward the M1 phenotype 
for an extended period following CNS injury, with corresponding negative effects 
on recovery. This contrasts with the typical immune response outside neural tissue, 
where an early increase in M1 macrophages gives way to pro-recovery M2 macro-
phages [46]. The neurotoxic effect of M1 macrophages is most likely mediated by 
pro-inflammatory cytokines. Levels of M1-associated pro-inflammatory cytokines 
transiently increase in brain tissue during the acute response to injury. Specifically, 
IL-1β, IL-6, and TNFα levels have been shown to significantly increase in brain tissue 
by 12 hours postinjury in a mouse model. These cytokines return to sham levels by 
7 days postinjury [50]. Support for the importance of these cytokines as mediators of 
M1-induced secondary neural damage following TBI is provided by a study targeting 
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these cytokines as a potential TBI therapeutic. For example, treatment with Minozac, 
an inhibitor of pro-inflammatory cytokines, ameliorated the TBI-induced increase 
of pro-inflammatory cytokines in cortex and hippocampus and resulted in decreased 
neuronal damage and improved neurocognitive function following TBI [50].
6.2 Pro-resolving macrophages in TBI (M2 phenotype): time course
The alternatively activated or M2 phenotypic macrophages are known to serve as 
pro-recovery or anti-inflammatory cells. These cells are activated by IL4 and serve 
an immunoregulatory function, in contrast to the microbe-killing function of their 
M1 counterparts [47]. Like M1 macrophages, identification of M2 macrophages 
employs gene expression levels of a wide array of characteristic markers. Markers 
commonly used for this purpose include CD206, Fizz1, Ym1, IL1-RN, Arg1, TGFβ, 
SOCS3, and IL4-RA [46]. Low levels of CCR2 with high CX3CR1 expression have 
also been used as a marker for pro-repair macrophages [49]. Studies using these 
markers have demonstrated an important role for M2-polarized macrophages at 
multiple time points following TBI. Increases in M2 markers have been shown as 
early as 6 hours following CCI injury [46]. The reported timeline of M2 influence 
varies depending on the specific markers assessed. For example, the number of 
TGFβ-expressing macrophages/microglia has been demonstrated to increase by 
24 hours post-CCI injury and remain elevated compared to sham out to 7 days 
following injury [46]. Increase in expression of Arg1 has also been demonstrated in 
macrophages/microglia following CCI. Interestingly, the increase in Arg1 expres-
sion in macrophages/microglia, which first becomes evident at 24 hours post-CCI, 
continues to rise out to 7 days postinjury rather than decreasing back toward normal 
levels as was observed for TGFβ [46]. Expression of CD163, another marker of the 
pro-resolving M2 phenotype, has also been investigated following TBI. One study 
showed increased expression of CD163+ macrophages following weight-drop TBI 
in a rat model. This may have anti-inflammatory effects following TBI through 
suppression of the pro-inflammatory macrophage phenotype [51]. While timing 
of expression of specific markers can vary, these studies indicate that macrophages 
expressing M2 phenotypic traits are a significant factor in TBI recovery.
Macrophage polarization toward the alternatively activated or M2 phenotype 
has beneficial effects on recovery following TBI through a variety of mecha-
nisms. M2-polarized macrophages are characterized by expression of multiple 
markers including arginase 1 (Arg1), CD206, CD301, resistin-like α, and PDL2 
[48]. Alternatively activated macrophages have been shown to decrease T-cell 
proliferation, promote angiogenesis, assist in generation of extracellular matrix 
components, and benefit wound healing and tissue repair [47]. In addition, the 
anti-inflammatory cytokines TGFβ and IL10 secreted by alternatively activated 
macrophages help to decrease activation of classical macrophages, reducing 
bystander tissue damage [47]. One study demonstrated that experimentally alter-
ing macrophage/microglia phenotype to favor M2 polarization by inhibition of 
NOX2 results in decreased oxidative damage [46]. In another report, inhibition 
of high-mobility group box 1 (HMGB1) decreased M1 and increased M2 polariza-
tion of macrophages/microglia, which correlated with decreased lesion volume 
and improved recovery [52]. Moreover, activation of the cannabinoid receptor 
CB2R decreased M1 and promoted M2 macrophage polarization, accompanied by 
decreased edema and improved blood flow and behavioral recovery [53]. These 
studies employed different methods to influence macrophages toward the M2 phe-
notype with similar results—increased expression of M2 traits has a positive impact 
on TBI recovery. Additional studies are needed to confirm this beneficial role of M2 
macrophages in TBI.
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7. Continuum of expression between M1/2 and influence on TBI
As previously mentioned, macrophages in vivo do not always show a sharply 
demarcated M1 or M2 phenotype. Several studies have shown expression of both 
M1 and M2 traits in macrophages following TBI, while others have demonstrated 
that macrophages can switch between phenotypes [54, 55]. One study using the CCI 
model demonstrated co-expression of iNOS, a classical M1 marker, with Arg1, an 
M2 marker, in perilesional macrophages/microglia following injury [46]. Another 
study assessed expression of a wide array of pro-inflammatory (associated with 
M1) and anti-inflammatory (associated with M2) genes in mouse cortical tissue 
following CCI injury and found that both sets of genes are co-expressed at 1, 2, and 
7 days postinjury. This study also showed that perilesional microglia/macrophages 
co-labeled with both M1 and M2 markers at all three time points [56]. A different 
study using flow cytometry to sort Arg1-positive and Arg1-negative brain mac-
rophages following TBI demonstrated that neither Arg1+ or Arg1− cells displayed 
gene expression profiles consistent with the M1 or M2 patterns defined by in vitro 
studies, although two distinct populations of macrophages did seem to exist in this 
context [48]. These findings suggest that the classic M1 and M2 traits may actually 
coexist in the same macrophages following TBI. To confirm this at the level of the 
individual macrophage, one study employed single-cell RNA sequencing to assess 
the expression of classical and alternative markers in individual macrophages 
1 day following TBI. This work demonstrated that traditional M1/2 markers are 
frequently co-expressed at high levels in the same cell [55]. This study also dem-
onstrated that high expression of well-known M1 or M2 markers did not seem to 
down-regulate expression of markers of the opposite class. Some macrophages with 
high expression of Arg1, an established M2 marker, also displayed high expression 
of TNF and/or IL-1β, known M1 markers [55]. This type of M1/2 combination 
profile was displayed in a variety of genes, demonstrating that macrophage polar-
ization in vivo can widely differ from the traditional M1/2 paradigm established 
primarily by in vitro studies [55]. Surprisingly, this study actually failed to find 
any macrophages that fit entirely within the M1 or M2 category, suggesting that 
all macrophages responding to TBI respond to injury stimuli along a continuum of 
expression [55]. Intermediate macrophage phenotypes with traits of both M1 and 
M2 have also been found in studies of spinal cord injury and Alzheimer’s disease 
[46]. The results of these studies indicate the existence of a continuum between M1 
and M2 macrophages in the setting of brain injury and disease.
The specific stimuli and mechanisms involved in the continuum of M1/2 
expression are currently areas of active research. Some authors have suggested that 
dual expression of M1 and M2 characteristics is a necessary part of the macrophage 
response to TBI, as these cells must respond to both pro- and anti-inflammatory 
environmental signals simultaneously in the setting of brain trauma [54]. This 
concept is supported by the results of the previously mentioned study demonstrat-
ing concurrent expression of both pro- and anti-inflammatory gene signatures 
[56]. The function of infiltrating monocyte/macrophages, therefore, appears to 
depend more on the specific gene expression and cytokine profile than on overall 
classification as M1 or M2. These findings underscore the importance of improving 
our understanding of the pathways involved in regulation of expression on the M1/2 
continuum. Data from multiple studies have indicated that the Tie2/Angiopoietin 
pathway is an important factor in the continuum of expression between M1 and M2 
macrophages. In addition, data from our project, to be discussed in the following 
chapters, have specifically implicated this pathway in the context of M1/2 polariza-
tion after TBI.
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8. Tie2/Angiopoietin signaling in immune cells
The Tie2/Angiopoietin signaling axis was first identified for its key role in 
the regulation of angiogenic pathways, but this receptor complex is also gain-
ing increasing recognition for its importance in peripheral immune cells. The 
receptor tyrosine kinase Tie2 (also known as Tek) interacts with its ligands, the 
angiopoietin family of proteins, to influence vascular development [57]. Studies 
in endothelial cells have shown that Tie2 is differentially regulated by its ligands 
Angiopoietin 1 (Angpt1) and Angiopoietin 2 (Angpt2). Angpt1 typically acts as 
an agonist for Tie2, while Angpt2 serves as an antagonist with several exceptions 
[58, 59]. Although Tie2/Angiopoietin signaling has been most studied for its role 
in regulation of vascular function, Tie2 is also expressed in a subpopulation of 
monocyte/macrophages called Tie2-expressing monocytes (TEMs) implicated in 
tumor formation and inflammation [60]. This review will discuss the mechanisms 
involved in the Tie2/Angiopoietin signaling axis and investigate the function of 
TEMs in various cellular contexts.
8.1 Overview of the Tie2/Angiopoietin axis
Tie2 is a receptor tyrosine kinase first identified on vascular endothelial cells 
[61]. There are multiple components to the Tie2 signaling pathway where the 
angiopoietin ligands serve as binding partners [59]. In addition to its expression on 
endothelial cells, Tie2 is expressed in TEMs, hematopoietic stem cells, neutrophils, 
eosinophils, and some muscle satellite cells [59, 62]. Angiopoietin 1 (Angpt1) 
is primarily expressed in platelets and perivascular cells, while Angiopoietin 2 
(Angpt2) is expressed in endothelial cells [63]. Expression of both Angiopoietins 
has also been demonstrated in hematopoietic stem cells and some immune cell 
types including monocyte/macrophages [64, 65]. Angpt1 serves as a Tie2 agonist, 
activating this receptor and increasing endothelial vessel stability [59]. However, 
the function of Angiopoietin 2 (Angpt2) is more variable. Some studies have 
shown that Angpt2 can act as either an agonist or antagonist of Tie2 depending on 
cellular context, and increased expression of Angpt2 has been demonstrated in 
multiple disease states [59]. Angpt2 has been found to act as a Tie2 agonist in the 
context of decreased Angpt1 signaling, absence of Tie1/Tie2 heterocomplexes, or 
inhibition of vascular endothelial protein tyrosine phosphatase (VE-PTP) in the 
endothelium [59, 66, 67]. However, the dominant role of Angpt2 and/or these co-
complexes in TBI has not been established. This ligand has repeatedly been shown 
to act as an antagonist in the setting of inflammation [68]. Although less studied 
than its counterpart, Tie1 has also been found to interact with Tie2 to promote 
Tie2/Angiopoietin interactions in vascular remodeling [59, 69]. The interactions 
between Tie2, Tie1, Angpt1, and Angpt2 have a profound influence on cell survival 
and vascular permeability [59, 61].
The downstream cellular effects of Tie2 binding with an Angiopoietin ligand 
can vary widely with cellular context. This is partially due to the differing effects 
of Angpt1 vs. Angpt2—Angpt1 binding has been shown to oppose the effects of 
inflammatory cytokines and decrease vascular permeability, while Angpt2 has 
been found to increase vascular permeability in a number of inflammatory models 
[59]. Binding patterns of these two ligands with Tie2 are distinct from each other, 
which may contribute to their differing effects. The fibrinogen-like domain of 
Angpt1 binds an immunoglobulin domain of Tie2, which may help Angpt1 increase 
cluster formation and cross-phosphorylation of Tie2 upon binding [68]. In contrast, 
Angpt2 has a slightly different amino acid sequence in the fibrinogen-like domain 
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and is also more likely to form dimers than oligomers. These structural differences 
may contribute to the different effects of the two ligands [68]. The central impor-
tance of clustering in Tie2 activation is confirmed by the results of one study that 
used an anti-Angpt2 antibody to cluster Angpt2. The clustering of Angpt2 caused it 
to act as an agonist to Tie2 rather than an antagonist, resulting in decreased vascular 
permeability and increased organ protection in the setting of sepsis [70]. Once Tie2 
is activated, multiple downstream signaling pathways could be involved as effec-
tors. Specifically, the Akt/PI3K (phosphatidylinositol 3 kinase) pathway has been 
implicated as a downstream effector of Tie2. This pathway is critical for cell survival 
and M2 macrophage polarization [61, 71, 72]. In the context of inflammation, Tie2 
activation is decreased by a variety of mechanisms, (1) Angpt2 can be released 
from endothelial cells and competitively inhibits Angpt1/Tie2 binding, (2) overall 
expression of Tie2 and Angpt1 may be decreased, or (3) the extracellular domain 
of Tie2 can be cleaved [68]. The decrease in Tie2-Akt/PI3K signaling up-regulates 
Angpt2. This creates a feedback loop that further decreases Tie2 signaling [68]. The 
overall effect of the increasing endothelial-derived Angpt2 signaling is an increase 
in vascular permeability and amplification of inflammatory processes; however, 
these effects in the brain have not been established following TBI-induced neuroin-
flammation [63].
While expression of Tie2 has been most studied in endothelial cells, Tie2 has 
also been shown to be expressed in hematopoietic cell types. The role of Tie2 has 
been studied in hematopoietic stem cells and a subset of monocytes in addition to 
vascular and lymphatic endothelial cells [59]. Interestingly, Tie2 expression has 
also been demonstrated on neutrophils—Angiopoietin 1 has been shown to interact 
with Tie2 on neutrophils to promote neutrophil migration [73]. The role of Tie2 in 
macrophages has been increasingly recognized for its importance in tumorigenesis 
and inflammation. This critical function of Tie2 signaling will be discussed in the 
following sections of this review.
8.2 Tie2-expressing macrophages
Tie2 has been shown to play an important role in a subset of monocyte/mac-
rophages known as Tie2-expressing monocytes or macrophages (TEMs). TEMs 
have been most studied in the setting of tumorigenesis and have been found 
to promote tumor development through a variety of mechanisms. In addition 
to potentiating overall tumor growth and metastasis, TEMs have been demon-
strated to directly promote tumor angiogenesis [74]. Other research has shown 
that TEMs not only promote tumorigenesis but are necessary for tumor angio-
genesis and tumor recurrence following chemotherapy [75]. Several mechanisms 
have been proposed as effectors of this process. The interaction of Angpt2 with 
Tie2 in TEMs has been implicated in the pro-angiogenic effect of TEMs as well as 
in metastasis. One study found that inhibition of Angpt2 blocked the pro-angio-
genic function of TEMs in tumors, and another study suggested that inhibition 
of Angpt2 could help to limit metastasis [59]. Tumor-associated expression of 
Angpt2 has also been shown to increase expression of pro-angiogenic factors 
in TEMs [76]. In addition, TEMs in tumors display increased expression of the 
anti-inflammatory cytokine IL-10. Stimulation of these cells by Angpt2 can work 
through IL-10 to influence activity of T cells by decreasing T-cell proliferation 
and increasing regulatory T cells for an overall immunosuppressive effect [77]. 
Angpt1-Tie2 interaction may also influence tumor development. TEMs are known 
to express Angpt1 [78], indicating that they may be able to activate Tie2 through 
autocrine signaling. Angpt1 expression in tumor-infiltrating TEMs has been sug-
gested as a mechanism of increasing tumor angiogenesis through interaction with 
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endothelial cells [78]. While both Angpt1 and Angpt2 may influence the tumor-
promoting activity of TEMs, studies agree that the protumorigenic activity of 
these cells is under control of Tie2/Angiopoietin signaling. This discovery has 
established the Tie2/Angiopoietin signaling axis as a target of interest in tumor 
therapeutic research. Several treatments aimed at blocking Tie2/Angiopoietin 
signaling are currently in development, with three Tie2/Angiopoietin inhibitors 
currently in clinical trials as cancer therapeutics [79]. No trials are currently 
underway for brain injury.
The origin and M1/2 polarization status of TEMS is currently under active 
investigation. Some studies have found that these cells seem to be polarized 
toward the M2 phenotype [80]. TEMs have been shown to display increased 
expression of arginase 1 (Arg1) and scavenger receptors accompanied by 
decreased expression of pro-inflammatory and anti-angiogenic mediators com-
pared to tumor-associated macrophages that lack Tie2 expression. This expression 
pattern is consistent with an M2 polarization state [78]. In addition, TEMs exert 
an anti-inflammatory effect in the context of tumorigenesis. These cells release 
IL-10 and VEGF, decrease T-cell proliferation, inhibit antigen presentation by 
dendritic cells, and promote T-cell conversion to regulatory T cells [80]. However, 
TEMs may also play important roles in a variety of disease settings aside from 
tumorigenesis. Specifically, many studies have implicated TEMs as key regulators 
of inflammation.
9. TEMs in inflammation
An influential role of TEMs under inflammatory conditions remains under 
investigation. In the setting of inflammation, Tie2 expression may influence 
macrophage phenotype on the M1/2 continuum [45]. While TEMs have been shown 
to favor the M2 phenotype in the context of tumor infiltration, Tie2 expression 
has been demonstrated in monocytes polarized to both M1 and M2 phenotypes 
[60, 78]. Investigations of whether Tie2 expression in inflammatory disease cor-
relates with M1 or M2 phenotype have shown conflicting results. One study showed 
Tie2 activation in synovial macrophages of human patients with autoimmune 
rheumatoid arthritis. In this study, Angpt2/Tie2 signaling interacted with TNF to 
up-regulate IL-6 and macrophage inflammatory protein 1α (MIP-1α), and antago-
nizing this pathway reduced synovial inflammation in a mouse model of disease 
[81]. Exogenous Angpt1 application to human monocyte cultures has been shown to 
up-regulate TNF and possibly regulate their polarization state [45]. Another study 
found that Angiopoietin binding works synergistically with TNF to drive expres-
sion of pro-inflammatory cytokines in human-cultured monocytes under several 
polarized conditions [60]. In contrast, previous studies showed anti-inflammatory 
effects of Angpt1 binding in TEMs and found that Angpt1 blocks LPS-induced TEM 
migration and ameliorates LPS-induced TNF expression via NF-ΚB [82]. Angpt2 
has also been shown to augment immunosuppressive cytokines and T-reg chemo-
kines expressed by TEMS in vitro [77]. These conflicting results suggest that Tie2 
signaling may serve differential functions depending on acute and chronic condi-
tions and may be dependent upon the activation state of the cells. Furthermore, the 
role of clustering and oligomerization of angiopoietin molecules on Tie2 binding 
and activation [83] raises the possibility that Tie2 may be differentially regulated 
under these conditions, although individual studies failed to confirm p-Tie2 states 
directly. Therefore, the role of Tie2 activation in the M1/M2 continuum remains 
unclear. While Tie2 signaling has been implicated in promoting injury-induced and 
tumor-promoting vascular health in numerous non-CNS models [59, 74, 75], its role 
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in regulating monocyte/macrophage polarization in CNS inflammation remains 
unexplored. Furthermore, limited data exist regarding novel pathways that may 
regulate Tie2 function in TBI-induced peripheral immune response.
10. Cell-to-cell contact in TBI-induced inflammation
Many cell-to-cell interactions become key in the regulation of inflammation 
following TBI. As previously mentioned, one of the most detrimental results of 
TBI is the breakdown of the BBB. Adhesion molecules contribute to cell-cell and 
cell-extracellular matrix (ECM) interactions that mediate inflammation by promot-
ing peripheral leukocyte infiltration across the BBB and aggregation to the site of 
injury. This represents the initiation of the inflammatory response [84]. After tissue 
injury, circulating immune cells will recognize signals released from injured tissue, 
will stop on the luminal surface of blood vessels, transmigrate paracellularly across 
the endothelial layer, and enter the injured milieu [85, 86]. This process is referred 
to as the leukocyte adhesion cascade, which involves tethering, rolling, activation, 
firm adhesion, and transmigration. Numerous preclinical models have determined 
the detrimental role of leukocyte migration and accumulation during neuroinflam-
mation in TBI [39, 87].
10.1 Adhesion molecules involved in TBI-induced inflammation
Adhesion molecules involved in these processes include three major families: 
selectins, integrins, and immunoglobulins. Selectins are a group of transmembrane 
glycoproteins expressed on the surface of leukocytes, which express L-selectin, 
and endothelial cells, which express P- and E-selectins following activation [88]. 
These glycoproteins mediate the initial tethering of leukocytes to the vessel wall 
by binding to counter-receptors and rolling within moments of tissue injury [89]. 
Integrins are a family of adhesion molecules broken into subclassifications of α and 
β subunits that are responsible for cellular attachment to the ECM and leukocyte-
endothelial cell adhesion and are denominated by the β subunit CD18. These 
molecules include CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), CD11c/CD18, and 
CD11d/CD18 [90, 91]. Immunoglobulins are a superfamily in which some members 
are glycoprotein adhesion molecules that regulate the adhesion and migration 
between leukocytes and endothelial cells during the inflammatory process. These 
molecules include ICAM-1, ICAM-2, VCAM-1, and PECAM-1 [92]. Key adhesion 
molecules involved in TBI inflammatory response are summarized in Table 1. Eph 
receptors and their ephrin ligands have also been implicated in the migration step of 
leukocyte infiltration into injured tissue and subsequent inflammation and will be 
discussed further.
10.2 Overview of membrane-bound Eph receptors and ephrin ligands
Eph receptors tyrosine kinases and their membrane-bound ephrin ligands 
function as mediators of cell migration and a wide-range of cellular functions 
across different cell types. Eph receptors are the largest family of receptor tyrosine 
kinases that are activated following cell-to-cell contact [107]. The Eph receptors 
are classified as either EphA or EphB receptors based on ligand binding. EphB 
receptors typically bind to transmembrane ephrin B ligands  [107–109], while some 
Eph receptors, such as EphA4, can bind to both A and B ephrins [110]. Eph recep-
tors play critical roles in axon guidance, synaptogenesis, neuromuscular junctions, 
and vascular remodeling among other roles [107, 109, 111]. Importantly, multiple 
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Adhesion 
molecule family
Molecule Involvement/association with TBI Expression Mediates
Selectin E-selectin 
(CD62E, 
ELAM-1)
Up-regulated 2–24 hrs in percussion model of TBI in rats, activated by IL-1 and 
TNFα [93].
Activated endothelial 
cells
Slow leukocyte rolling
P-selectin 
(CD62P)
Increased CSF levels in children with severe TBI and associated with poor 
outcome [94]. Stimulated by TNFα and IL-1 [95].
Secretory granules 
of platelets and 
endothelial cells
Leukocyte rolling
Integrins CD11b Depletion of CD11b macrophages in diphtheria toxin receptor mice increased 
inflammatory signaling during TBI [96]. This may be due to critical 
mechanisms for TBI recovery being impaired.
Macrophages and 
microglia
Pathogen and DAMP recognition, 
phagocytosis, and cell survival [97]
CD18/CD11b 
(Mac-1)
Blockade attenuates neutrophil accumulation following TBI in rats [98]. Neutrophils, 
monocytes/
macrophages, and 
NK cells
Firm adhesion during transmigration of 
leukocytes
CD18/CD11d Blockade reduces lesion volume and macrophage infiltration 3 d post-TBI in rats 
[99].
Neutrophils 
and monocyte/
macrophages
Adhesion of leukocytes
Immunoglobulin ICAM-1 Increased significantly in TBI up to 72 hours postinjury, and blockade reduced 
leukocyte accumulation and improved neurological function following TBI 
[100, 101]. Soluble ICAM-1 in CSF was found in patients with severe cerebral 
injuries and BBB impairment [102]. Stimulated by IL-8, IL-1, and TNFα.
Endothelial cells Leukocyte passage across vascular 
endothelial cell layer to injured tissue. 
Promotes leukocyte adhesion and 
migration [103]
VCAM-1 Significantly decreased in children suffering from inflicted TBI [104]. Activated endothelial 
cells [105]
Promotes leukocyte adhesion through 
VLA-4 receptor [106]
Table 1. 
Adhesion molecules involved in TBI inflammatory response.
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Eph receptors and ephrins play a critical role in inflammation [111]. Ephrin A1 in 
endothelial cells responds to TNF stimulation, and multiple Eph receptors and 
ephrins respond to LPS [111]. EphA4 has been demonstrated to influence both 
spinal cord injury and TBI [111, 112].
10.3 Eph signaling in immune cells
Eph/ephrin signaling contributes to immune cell function. For example, 
EphA4 expression influences multiple different immune cell types including T 
cells, B cells, platelets, monocyte/macrophages, and dendritic cells [113–115]. 
Both CD4+ and CD8+ T cells have been shown to express EphA4 [116], and EphA4 
expression in CD4+ T cells has been implicated in T-cell migration [117, 118]. 
EphA4 is also critical in migration of memory T cells in response to ephrin A1 
stimulation [116]. EphA4 expression in monocyte/macrophages effects their 
polarization status by mediating their pro-inflammatory (M1-like) state [115]. 
Moreover, ephrin A1 stimulation increased monocyte adhesion in a cell culture 
model through interaction with EphA4 on endothelial cells [119]. While these 
studies highlight that Eph/ephrin signaling is important in peripheral-derived 
immune cells, a significant research gap exists concerning the specific mecha-
nisms involved in bi-direction signaling and its role in the function of peripheral 
immune cells following TBI.
11. Conclusions
Understanding the role of the peripheral-derived immune response to TBI 
is an important unmet need in TBI research. TBI is a leading cause of death and 
disability worldwide, and the secondary phase of injury is a critical target for 
therapeutics. Infiltration of peripheral immune cells through the compromised 
blood-brain barrier forms a major component of this phase, which can have both 
beneficial and deleterious effects. Monocyte/macrophages impact the response 
to TBI by a variety of mechanisms. These cells can cause tissue damage through 
pro-inflammatory traits or exert pro-recovery effects through anti-inflammatory 
traits, and the continuum of M1/2 expression is a growing research focus. Tie2 and 
cell-to-cell contact signaling is gaining attention for its role in peripheral immune 
cells, which provides additional opportunity for developing novel therapeutic 
treatments following TBI.
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